Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
about
MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.Improved treatment of early small hepatocellular carcinoma using sorafenib in combination with radiofrequency ablation.The Role of MicroRNAs in Hepatocellular Carcinoma
P2860
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant sorafenib after hepte ...... tocellular carcinoma patients.
@en
Adjuvant sorafenib after hepte ...... tocellular carcinoma patients.
@nl
type
label
Adjuvant sorafenib after hepte ...... tocellular carcinoma patients.
@en
Adjuvant sorafenib after hepte ...... tocellular carcinoma patients.
@nl
prefLabel
Adjuvant sorafenib after hepte ...... tocellular carcinoma patients.
@en
Adjuvant sorafenib after hepte ...... tocellular carcinoma patients.
@nl
P2093
P2860
P356
P1476
Adjuvant sorafenib after hepte ...... tocellular carcinoma patients.
@en
P2093
Hong-Bo Huan
Kuan-Sheng Ma
Wan-Yee Lau
Xiao-Wu Li
Xu-Dong Wen
P2860
P304
P356
10.3748/WJG.V22.I23.5384
P407
P577
2016-06-01T00:00:00Z